| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/18/2010 | US20100040606 Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections |
| 02/18/2010 | US20100040605 Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same |
| 02/18/2010 | US20100040604 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
| 02/18/2010 | US20100040603 Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies |
| 02/18/2010 | US20100040602 Antibodies against Human Cytimegalovirus (HCMV) |
| 02/18/2010 | US20100040601 Compositions and methods for treating herpes simplex virus infections and related diseases |
| 02/18/2010 | US20100040600 Agents for Promoting the Growth of Hematopoietic Stem Cells |
| 02/18/2010 | US20100040576 Modified Oligonucleotides For The Treatment Of Hepatitis C Infection |
| 02/18/2010 | US20100040575 Use of inhibitors of glutaminyl cyclase and glutamate cyclase for treatment and prevention of neurodegenerative diseases |
| 02/18/2010 | US20100040574 TREATMENT OF CANCER WITH ANTI-IL-1alpha ANTIBODIES |
| 02/18/2010 | US20100040556 Carrier nanoparticles and related compositions, methods and systems |
| 02/18/2010 | US20100040541 Structural Variants of Antibodies for Improved Therapeutic Characteristics |
| 02/18/2010 | US20100040540 Anti cd44 antibodies for eradicating leukaemic stem cells and breast cancer stem cells |
| 02/18/2010 | US20100040539 Vector System |
| 02/18/2010 | US20100040537 antibodies that are wild-type, chimeric, CDR grafted and humanized; disease or disorder in which prostaglandin E2 activity is detrimental, such as cancer, atuoimmune diseases, inflammatory diseases |
| 02/18/2010 | CA2734379A1 Ragweed peptides for vaccine |
| 02/18/2010 | CA2734335A1 Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
| 02/18/2010 | CA2734147A1 Purine nucleoside phosphorylase as enzymatic activator of nucleoside prodrugs |
| 02/18/2010 | CA2734081A1 Combination therapy of hiv fusion/entry inhibitors targeting gp41 |
| 02/18/2010 | CA2733930A1 Anti-arrhythmia agents, methods of their use, methods of their identification, and kits therefore |
| 02/18/2010 | CA2733898A1 Polyvalent vaccine |
| 02/18/2010 | CA2733642A1 Anti-il-12/il-23 antibodies |
| 02/18/2010 | CA2731473A1 Carrier system for biological agents containing organosilicon compounds and uses thereof |
| 02/17/2010 | EP2154251A1 Expression system of recombinant proteins with enhanced yield and immunogenicity |
| 02/17/2010 | EP2154248A1 Compounds and methods for diagnosis of tuberculosis |
| 02/17/2010 | EP2154157A2 FC region variants |
| 02/17/2010 | EP2154149A1 A truncated l1 protein of human papillomavirus 6 |
| 02/17/2010 | EP2154148A1 A truncated l1 protein of human papillomavirus 11 |
| 02/17/2010 | EP2154147A1 A truncated l1 protein of human papillomavirus 16 |
| 02/17/2010 | EP2154146A1 Use of african swine pest haemoglutinin as an adjuvant |
| 02/17/2010 | EP2154145A2 Dimerized peptide |
| 02/17/2010 | EP2153848A2 Therapeutic monoclonal antibodies that neutralize botulinium neurotoxins |
| 02/17/2010 | EP2153847A1 Gene sensitive to bone/joint disease and use thereof |
| 02/17/2010 | EP2153846A1 Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immonostimulatory molecule |
| 02/17/2010 | EP2153845A1 Endoglin peptides, vaccines and methods for preparing the same |
| 02/17/2010 | EP2153843A1 Compositions and methods for the diagnosis and treatment of tumor |
| 02/17/2010 | EP2153841A1 Vaccine comprising Amb 1 a peptides for use in the treatment of ragweed allergy |
| 02/17/2010 | EP2153840A1 Therapeutic agent and detection reagent for arteriosclerotic disease which targets for thallusin |
| 02/17/2010 | EP2152863A1 Human parainfluenza viruses having separated p and c genes |
| 02/17/2010 | EP2152855A1 Recombinant protein production in avian ebx® cells |
| 02/17/2010 | EP2152755A1 Prevention and treatment of complement-associated eye conditions |
| 02/17/2010 | EP2152754A2 Monoclonal antibodies against claudin-18 for treatment of cancer |
| 02/17/2010 | EP2152753A1 Antibodies against ramp3 |
| 02/17/2010 | EP2152750A1 Anti-mdl-1 antibodies |
| 02/17/2010 | EP2152748A1 Anti-notch1 nrr antibodies and methods using same |
| 02/17/2010 | EP2152746A1 Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90 |
| 02/17/2010 | EP2152740A1 Products for altering il-33 activity and methods therefor |
| 02/17/2010 | EP2152736A1 Complement factor h-derived short consensus repeat-antibody constructs |
| 02/17/2010 | EP2152731A2 Klebsiella antigens |
| 02/17/2010 | EP2152729A1 Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines |
| 02/17/2010 | EP2152318A2 Uses and compositions for treatment of psoriasis and crohn's disease |
| 02/17/2010 | EP2152311A1 Set of means for treating a malignant pathology, an autoimmune disease or an infectious disease |
| 02/17/2010 | EP2152310A2 Methods for administering anti-il-5 antibodies |
| 02/17/2010 | EP2152309A1 Methods and device to neutralize soluble toxic agents in the brain |
| 02/17/2010 | EP2152308A1 New indications for anti- il-i-beta therapy |
| 02/17/2010 | EP2152307A1 Inhibition of tumor metastasis by anti neuropilin 2 antibodies |
| 02/17/2010 | EP2152306A2 Prrsv vaccins based on gp5 proteins |
| 02/17/2010 | EP2152304A1 Nanoemulsion therapeutic compositions and methods of using the same |
| 02/17/2010 | EP2152303A1 Chlamydial antigens as reagents for diagnosis and treatment of chlamydial infection and disease |
| 02/17/2010 | EP2152301A2 Trypanosoma antigens, vaccine compositions, and related methods |
| 02/17/2010 | EP1578919B1 Endogenous retrovirus up-regulated in prostate cancer |
| 02/17/2010 | EP1549322B1 Lipid a and other carbohydrate ligand analogs |
| 02/17/2010 | EP1404816B1 Human hepatoma cell lines, methods for obtaining same and uses thereof |
| 02/17/2010 | EP1263954B1 Low density liprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 02/17/2010 | EP1240186B1 Improvements in or relating to immune responses to hiv |
| 02/17/2010 | EP1200132B2 Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines |
| 02/17/2010 | EP1117783B1 Gene expressed in prostate cancer |
| 02/17/2010 | EP1071700B1 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| 02/17/2010 | CN101652146A New abeta conformer selective anti-abeta globulomer monoclonal antibodies |
| 02/17/2010 | CN101649351A Methods for diagnosis and therapy of cancer and composition useful therein |
| 02/17/2010 | CN101648013A Preparation method of inactivated vaccine of infectious coryza of chicken |
| 02/17/2010 | CN101648012A Novel formulations of tumour-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules for vaccines |
| 02/17/2010 | CN101648011A Tumor targeting recombinant DNA vaccine, preparation method thereof and application thereof |
| 02/17/2010 | CN100590131C Methods and compounds for the targeting of protein to exosomes |
| 02/17/2010 | CN100589845C Anti-neovasculature preparations for cancer |
| 02/17/2010 | CN100589842C Molecular antigen array |
| 02/17/2010 | CN100589796C Highly efficient delivery of large therapeutic mass aerosol |
| 02/16/2010 | US7662949 Immunostimulatory oligoribonucleotides |
| 02/16/2010 | US7662936 Mass spectrometry of antibody conjugates |
| 02/16/2010 | US7662932 Endothelial growth factor; isolated polypeptide; stimulate cell proliferation, neovascularization, vascular system permeability |
| 02/16/2010 | US7662930 Polishing steps used in multi-step protein purification processes |
| 02/16/2010 | US7662929 Enzyme is a drug target; cancer, inflammatory diseases such as psoriasis |
| 02/16/2010 | US7662928 Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| 02/16/2010 | US7662926 Selectively bind human FcyRIIB, with little or no binding to other human Fc gamma Rs, e.g., human Fc gamma RIIA; atherosclerosis; leukocyte adhesion deficiency; rheumatoid arthritis; systemic lupus erythematosus (SLE); diabetes mellitus; multiple sclerosis; Reynaud's syndrome; autoimmune thyroiditis; |
| 02/16/2010 | US7662921 Methods of treating viral disorders |
| 02/16/2010 | US7662919 Notch-based fusion proteins and uses thereof |
| 02/16/2010 | US7662916 Modified HIV Env polypeptides |
| 02/16/2010 | US7662794 DNA enzyme to inhibit plasminogen activator inhibitor-1 |
| 02/16/2010 | US7662772 Methods for treating congestive heart failure |
| 02/16/2010 | US7662642 Method for detection of specific antibodies using ubiquitin fusion proteins |
| 02/16/2010 | US7662633 Method of screening for inhibitors of osteopontin |
| 02/16/2010 | US7662627 Adeno-associated virus materials and methods |
| 02/16/2010 | US7662622 Flea peritrophin nucleic acid molecules |
| 02/16/2010 | US7662590 Produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins; has anti-hepatitis activity; culturing |
| 02/16/2010 | US7662589 Produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins; has anti-hepatitis activity; culturing |
| 02/16/2010 | US7662588 Producing vaccines; cloning and identification of novel outer membrane proteins (OMP); isolating recombinant polypeptides |
| 02/16/2010 | US7662575 identifying Francisella tularensis vaccine candidates. It enables identification of novel vaccine candidates and quality assurance for vaccine batches, assessment of protection in vaccinates and identification of the infecting agent in vaccinates. Mice were first vaccinated with Brucella infections |
| 02/16/2010 | US7662548 Method of screening for modulators of HIV infection |
| 02/16/2010 | US7662401 administering combination of extract of Vitreoscilla filiformis bacteria and lycopene as antioxidant for limiting and/or eliminating objectionable body odors caused by skin lipid oxidation; catalase or peroxidase activity |
| 02/16/2010 | US7662400 antibodies |